For Immediate Release - November 17, 2003

The patented ATECT system is used to obtain tissue samples during a vacuum assisted breast biopsy procedure. It is a reliable diagnostic alternative to open surgical biopsy and can obtain multiple samples through a single, small incision in the skin, under local anesthesia. Open surgical biopsy removes a larger section of tissue through a 1 - 3 inch incision, often under general anesthesia and with significantly longer recovery periods and scarring. The ATECT system is fully compatible with Hologic's stereotactic breast biopsy systems, the MultiCare Platinum and StereoLoc II, which offer advanced digital imaging to pinpoint the precise location of areas for biopsy.

"We are pleased to have the opportunity to offer this leading-edge technology to physicians and their patients," said Jack Cumming, Hologic's Chairman and CEO. "Our stereotactic biopsy systems are designed to facilitate highly precise, image-guided procedures under minimally invasive conditions, while the ATECT system provides advanced technology to allow for faster, easier and more accurate sample collection than ever before. This agreement will help expand access to this valuable technology, while significantly complementing Hologic's comprehensive portfolio of products for the early detection of breast cancer and osteoporosis. We look forward to a mutually beneficial and productive relationship with our new partners at Suros."

Biopsy is the most widely accepted method for definitively determining the presence or absence of cancer following detection of a breast abnormality. An estimated 1.4 million women will undergo a breast biopsy this year. The availability of stereotactic biopsy has significantly lowered the number of open surgical procedures performed over the last decade, giving women an improved and more preferred choice in diagnosing breast disease or cancer.

"Our newly formed partnership with Hologic provides Suros an opportunity to expand its market reach and ability to improve patient care with a more efficient and effective breast biopsy device for both physicians and patients," said Jim Pearson, President and CEO of Suros. "When we can forge partnerships like this that get the best products in the hands of physicians who are impacting women's healthcare in communities all across the country, we know we are moving in the right direction. We are eager to begin a strong relationship with our colleagues at Hologic."

This News Release contains forward-looking information that involves risks and uncertainties, including statements about Hologic's plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the relationship and anticipated benefits from Hologic's agreement with Suros Surgical Systems, Inc.. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, Hologic's and Suros' limited experience in working together; Hologic's substantial dependence on the efforts of Suros to make this relationship successful; Hologic's ability to predict accurately the demand for its products and to develop strategies to address its markets successfully; uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, such as the ability to obtain FDA approval to market products developed, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the early stage of market development for digital x-ray products; risks relating to Hologic's reliance on a single source of supply for some key components of its products; the need to comply with especially high standards in the manufacture of digital x-ray products; Hologic's ongoing ability to satisfy financial and other covenants in its credit and lease agreements; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and reimbursement policies for the use of Hologic's products. Other factors that could adversely affect Hologic's business and prospects are described in Hologic's filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic's expectations or any change in events, conditions or circumstances on which any such statement is based.